As a new company with plans to scale quickly, it was important for Arranta Bio to set their vision at an early stage to help their employees embrace what it means to be a leading-edge CDMO. At its core, the company’s mission is to change healthcare by supporting the needs of industry pioneers and supplying breakthrough therapies that transform lives. But to bring this dream to reality, Arranta Bio’s team must be eager, intrepid, and daring.
To craft their core values, the team collaborated in defining what it means to be ALIVE: Agile, Leading, Innovating, Value-Creating, and Engaging. All employees participated in this exercise, which helped the company better understand what each core value means to individual employees. The roadmap for how the team should treat their clients, their work, and each other was the result of this process. The company believes these values will enhance the work they do to support the microbiome industry — and help them recruit and retain high-value employees.
Process development is a critical piece of the plan to become a best-in-class CDMO, and interest in this sector of the business is gathering momentum. Arranta Bio has recently committed to a $100M investment in their facilities to build end-to-end microbiome capacity. At the top of the list is the build-out of a process development lab in the Gainesville, Florida, facility, which will include space for several labs and workspace for 30 team members. The targeted completion date for this build-out is May 2020.
In the Watertown, Massachusetts, facility, Arranta Bio is working on significant renovations to office space, as well as the build-out for R&D laboratories and their first GMP area, which will hold a bank of eight cleanrooms and support space. These three initial phases are targeted for completion by the beginning of Q3 this year.
In January, Arranta announced two incredible additions to their senior leadership: Dave Stevens, COO, and Jason Rahal, SVP of Business Development. Both men bring proven experience and a track record of success and will be an integral part of building out the core teams and growing the business pipeline, respectively. As part of his business development initiatives, Jason and other key leaders in the company will be participating in a variety of trade shows and conferences in 2020, including the 2020 Microbiome Medicines Summit in March, the Translational Microbiome Conference in April, and the Microbiome Movement & Drug Development Summit in June. The senior leadership team strategically chose these conferences to place Arranta Bio leadership in the room with the brightest minds in the microbiome space.
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.
Arranta Bio is a CDMO specifically established to focus on serving companies seeking to develop and commercialize therapies targeting the human microbiome. Headed by a management team and technical experts with a proven track record, they offer the knowledge and resources necessary to help you to develop and manufacture promising new microbiome-based therapies to meet the needs of patients.